XT
REVB icon

XTX Topco’s Revelation Biosciences REVB Stock Holding History

XTX Topco’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,385
Closed -$13.7K – 4623
2026
Q1 		$13.7K Buy
11,385
+8,555
+302% +$16.5K ﹤0.01% 3629
2025
Q4 		$9.05K Buy
+2,830
New +$12.4K ﹤0.01% 3193
2025
Q1 		– Sell
-260
Closed -$23K – 2988
2024
Q4 		$23K Buy
+260
New +$34.6K ﹤0.01% 2018

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

XTX Topco's REVB Position: Q2 2026 in Review

XTX Topco sold out of Revelation Biosciences (REVB) in Q2 2026, closing a stake of 11,385 shares — an estimated $13.7K sold.

XTX Topco first reported a position in REVB in Q4 2024 and held it in 3 quarters. The position peaked at $23K in Q4 2024. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

  • XTX Topco reported no remaining Revelation Biosciences position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 11,385 Revelation Biosciences shares in Q2 2026, an estimated $13.7K.
  • XTX Topco first reported a position in Revelation Biosciences in Q4 2024 and held it in 3 quarters.
  • XTX Topco's Revelation Biosciences position peaked at $23K in Q4 2024.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.